WASHINGTON - Results from a U.S. trial of AstraZeneca’s COVID-19 vaccine may have included "outdated information" and that could mean the company provided an incomplete view of efficacy data, American federal health officials said early Tuesday.A spokesman from the drug company said Tuesday it was "looking into it."AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S.